Advances in the treatment of testicular cancer
- PMID: 26816836
- PMCID: PMC4708227
- DOI: 10.3978/j.issn.2223-4683.2015.06.02
Advances in the treatment of testicular cancer
Abstract
Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.
Keywords: Neoplasms germ cell tumor; chemotherapy; chemotherapy adjuvant; incidence; lymph node excision; neoplasm staging; orchiectomy; patient selection; treatment outcome.
Conflict of interest statement
References
-
- Bergström R, Adami HO, Möhner M, et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996;88:727-33. - PubMed
-
- Znaor A, Lortet-Tieulent J, Jemal A, et al. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014;65:1095-106. - PubMed
-
- Schmiedel S, Schüz J, Skakkebaek NE, et al. Testicular germ cell cancer incidence in an immigration perspective, Denmark, 1978 to 2003. J Urol 2010;183:1378-82. - PubMed
Publication types
LinkOut - more resources
Full Text Sources